The anti-polyubiquitylated conjugates mAb (FK2) demonstrate specific recognition of polyubiquitylated and monoubiquitylated proteins but shows no reactivity with free ubiquitin (Fujimoro et al. 1994). The anti-polyubiquitylated conjugates mAb (FK2) has been extensively characterised and used not only to investigate ubiquitin chain formation on poly and mono ubiquitylated proteins by Western blotting but also in the detection of intracellular polyubiquitin chains in immunoassays (Takada et al. 1995; Fujimoro et al. 2005).
References:
Fujimuro M, Sawada H, Yokosawa H (1994) Production and characterization of monoclonal antibodies specific to multiubiquitin chains of polyubiquitinated proteins. FEBS Lett 349173-180.
Takada K, Nasu H, Hibi N, Tsukada Y, Ohkawa K, Fujimuro M, Sawada H, Yokosawa H (1995) Immunoassay for the quantification of intracellular multi-ubiquitin chains. Eur J Biochem 233 42-47.
Fujimuro M, Yokosawa H (2005) Production of antipolyubiquitin monoclonal antibodies and their use for characterization and isolation of polyubiquitinated proteins. Methods Enzymol 39975-86.
bio-equip.cn
Ubiquigent Limited is a specialist developer and supplier of Drug Discovery Services, high quality Research Tools and Chemistry to the life science research community worldwide.
Ubiquigent’s scientific and business interests have a clear focus; namely the ubiquitin, ubiquitin-like, and integrated signalling systems.
The Company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery and pharmaceutical and biotechnology company scientists exploring the potential of ubiquitin cascade-focused drug discovery.
Ubiquigent benefits from high calibre backing including from private US investors, the UK Medical Research Council, and the University of Dundee. The Company’s headquarters and laboratory operations are based in the UK and are located in a state-of-the-art facility adjacent to the MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee (both founded by Professor Sir Philip Cohen). In addition to Ubiquigent’s own facilities and capabilities, such proximity provides ready access to a huge range of additional scientific expertise (1,000+ life-science researchers on site), technological competencies, and assay and analytical platforms.
Ubiquigent staff have a wealth of scientific experience, technological competencies and commercial expertise, gained from within academia, the life science research reagents and services sector, and the pharmaceutical industry, that enables the Company to offer a level of understanding and service to its customers and clients worldwide that few companies may match.
中文
